Lucid Diagnostics Inc. (LUCD) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

16/25

Growth 4 Margin 5 Expansion 3 Platform 2 Financial 2

latest quarter score

Earnings Reports

16
Lucid Diagnostics (LUCD) Q2 2026: EsoGuard Coverage Policy Unlocks Commercial Traction with 2,770 Tests Processed
August 17, 2026
11
Lucid Diagnostics (LUCD) Q1 2026: $16.8M Equity Raise Extends Runway as Medicare Decision Looms
May 15, 2026
13
Lucid Diagnostics (LUCD) Q4 2025: Test Volume Jumps 29% as VA and Medicare Access Catalysts Approach
March 26, 2026
9
Lucid Diagnostics (LUCD) Q3 2025: $27M Capital Raise Extends Runway as Medicare Coverage Decision Nears
November 12, 2025
10
Lucid Diagnostics (LUCD) Q2 2025: Commercial Revenue Jumps 40% as Medicare Coverage Milestone Nears
August 13, 2025
10
Lucid Diagnostics (LUCD) Q1 2025: Secures $40M Cash Runway to Accelerate EsoGuard Commercialization Amid Medicare Coverage Anticipation
May 14, 2025
11
Lucid Diagnostics (LUCD) Q4 2024: EsoGuard Test Volume Surges 84%, Setting Stage for 2025 Revenue Growth
March 24, 2025

Browse all companies